Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Psychiatry/Psychology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Memory Loss Clinical Trials

A listing of Memory Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (12) clinical trials

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease Inclusion Criteria: Dementia status of mild to moderate CT or MRI scan within 18 months prior ...

Phase

With age, some memory loss is normal. But it can also indicate the beginnings of Alzheimer’s. If you’ve noticed more forgetfulness and a decreased ability to function over the last year, you may be in the beginning stages of Alzheimer’s. If you have not been diagnosed and are between ages ...

Phase

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

This study is for patients with cognitive impairment or mild Alzheimer’s disease. Alzheimer’s disease is a slow progressive disease of the brain that affects memory and brain function. Currently available medications for Alzheimer’s disease provide limited symptomatic benefit and do not significantly change the course of the illness. This study ...

Phase

This study is for patients with cognitive impairment or mild Alzheimer’s disease. Alzheimer’s disease is a slow progressive disease of the brain that affects memory and brain function. Currently available medications for Alzheimer’s disease provide limited symptomatic benefit and do not significantly change the course of the illness. This study ...

Phase

The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...

Phase

DAYBREAK-ALZ — the study will last 8 weeks to see if you qualify, plus 3 years of treatment, then 4 weeks of follow-up. The study drug is a tablet, to be taken once a day. The tablet will contain either a lower dose of the study drug, a higher dose ...

Phase

Are you starting to experience memory problems? Are slight memory problems affecting your ability to do regular activities? Has anyone noticed a change in your memory? Do you have a family history of Alzheimer’s Disease? If so, you may be experiencing the first signs of memory loss. You may qualify ...

Phase

The primary objective of the study is to evaluate the efficacy of monthly doses of Aducanumab in slowing cognitive and functional impairment.

Phase